Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies
Clinical Pharmacology in Drug Development · 2025
DOI: 10.1002/cpdd.1522 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Clinical Pharmacology in Drug Development, 2025. Verfasst von Naihan Chen und 10 weiteren Autor:innen. Beteiligte Einrichtung: Development China - Oncology & Rare Disease Development, Clinical Pharmacology, Pfizer Inc, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Interferon-beta. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Dazukibart is a humanized monoclonal antibody selectively targeting interferon‐β. The pharmacokinetics (PK), safety, tolerability, and immunogenicity of dazukibart were evaluated in 2 double‐blind, randomized, placebo‐controlled, single‐dose, Phase 1 studies in healthy adults in China (Study 1: N = 18; dazukibart 900 mg = 15; placebo = 3) and Japan (Study 2: N = 12; Cohort 1: dazukibart 300 mg = 5, placebo = 1; and Cohort 2: dazukibart 900 mg = 5, placebo = 1). PK parameters were assessed after dosing in Study 1 and Study 2, and no significant differences were observed between PK findings among participants in both studies. A biphasic decline in dazukibart serum concentrations was observed in both studies. Exposures increased dose proportionally in Study 2. Body weight, but not race, was identified as an independent covariate of exposure using population PK modeling (including data from a Phase 1 US study [NCT02766621]). No deaths/discontinuations or serious/severe adverse events were observed, mostly mild adverse events were reported. No participants in Study 1 were antidrug antibody positive; 20.0% in Study 2 were positive for treatment‐induced antidrug antibodies and neutralizing antibodies. PK parameters and immunogenicity rates were consistent with the US study, and no new safety signals were identified.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Development China - Oncology & Rare Disease Development, Clinical Pharmacology, Pfizer Inc, Beijing, China.
- Clinical Pharmacology and Bioanalytics, Pfizer R&D Japan, Tokyo, Japan.
- Department of Respiratory and Critical Care Medicine, Peking University Third Hospital, Beijing, China.
- Dev China - Category 1, Pfizer Inc, Beijing, China.
- Inflammation & Immunology, Clinical Research, Pfizer R&D Japan, Tokyo, Japan.
- China Statistics, GBDM, Pfizer Inc, Shanghai, China.
Zitieren
APA
Chen, N., Sano, Y., Wang, X., Hu, S., Tabira, J., Luo, X., Yoshimatsu, H., Prybylski, J., Chu, M., Li, H., & Takazawa, K. (2025). Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies. Clinical Pharmacology in Drug Development. https://doi.org/10.1002/cpdd.1522
Vancouver
Chen N, Sano Y, Wang X, Hu S, Tabira J, Luo X, et al. Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies. Clinical Pharmacology in Drug Development. 2025. doi:10.1002/cpdd.1522
BibTeX
@article{Chen2025,
author = {Chen, Naihan and Sano, Yamato and Wang, Xiaohong and Hu, Shuiyi and Tabira, Junichi and Luo, Xin and Yoshimatsu, Hiroki and Prybylski, John and Chu, Myron and Li, Haiyan and Takazawa, Kenji},
title = {Pharmacokinetics, Safety, and Tolerability of Single‐Dose Dazukibart in Healthy Adults in China and Japan: Results From 2 Randomized, Double‐Blind, Phase 1 Studies},
journal = {Clinical Pharmacology in Drug Development},
year = {2025},
doi = {10.1002/cpdd.1522}
}
EUVIMED